$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000156459016013587 Filed on February 26, 2016

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$3.534B	$3.526B	$3.328B
YoY Change	6.18%	8.42%	8.64%
Cost Of Revenue	$2.515B	$2.501B	$2.367B
YoY Change	6.28%	7.5%	11.22%
Gross Profit	$1.019B	$1.025B	$961.6M
YoY Change	5.92%	10.74%	2.8%
Gross Profit Margin	28.82%	29.06%	28.89%
Selling, General & Admin	$407.6M	$356.0M	$360.8M
YoY Change	12.97%	8.94%	12.75%
% of Gross Profit	40.02%	34.74%	37.52%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$163.3M	$162.1M	$153.6M
YoY Change	6.32%	8.65%	10.74%
% of Gross Profit	16.03%	15.82%	15.97%
Operating Expenses	$571.0M	$518.1M	$513.9M
YoY Change	11.11%	8.84%	11.84%
Operating Profit	$244.9M	$509.4M	$452.1M
YoY Change	-45.82%	16.42%	-6.63%
Interest Expense	-$95.70M	-$100.7M	-$93.40M
YoY Change	2.46%	6.34%	-5.94%
% of Operating Profit	-39.07%	-19.77%	-20.66%
Other Income/Expense, Net	$4.600M	$2.500M	$200.0K
YoY Change	2200.0%	-300.64%	-94.29%
Pretax Income	$146.3M	$408.4M	$354.4M
YoY Change	-58.71%	21.39%	-6.75%
Income Tax	$111.8M	$147.1M	$104.0M
% Of Pretax Income	76.41%	36.02%	29.35%
Net Earnings	-$6.000M	$215.9M	$208.0M
YoY Change	-102.88%	17.24%	-2.01%
Net Earnings / Revenue	-0.17%	6.12%	6.25%
Basic Earnings Per Share	-$0.03	$1.02	$0.98
Diluted Earnings Per Share	-$0.03	$1.00	$0.96
COMMON SHARES
Basic Shares Outstanding			214.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.742B	$2.000B	$1.101B
YoY Change	58.23%	19.86%	13.36%
Cash & Equivalents	$1.245B	$1.047B	$736.9M
Short-Term Investments	$497.2M	$953.0M	$364.1M
Other Short-Term Assets	$190.3M	$429.0M	$186.8M
YoY Change	1.86%	149.05%	5.91%
Inventory	$185.6M	$173.0M	$136.1M
Prepaid Expenses	$105.2M		$102.5M
Receivables	$1.724B	$1.700B	$1.526B
Other Receivables	$435.9M	$466.0M	$400.9M
Total Short-Term Assets	$4.503B	$4.738B	$3.636B
YoY Change	23.85%	13.39%	4.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.789B	$2.622B	$2.469B
YoY Change	12.95%	11.14%	12.77%
Goodwill	$5.896B	$9.488B	$9.415B
YoY Change	-37.38%	1.53%	2.2%
Intangibles	$1.687B		$1.865B
YoY Change	-9.52%		-7.88%
Long-Term Investments	$167.0M	$158.0M	$155.0M
YoY Change	7.74%	2.6%	29.17%
Other Assets	$73.56M	$62.39M	$77.00M
YoY Change	-4.47%	-7.34%	-3.26%
Total Long-Term Assets	$14.01B	$14.16B	$13.98B
YoY Change	0.22%	1.68%	2.6%
TOTAL ASSETS
Total Short-Term Assets	$4.503B	$4.738B	$3.636B
Total Long-Term Assets	$14.01B	$14.16B	$13.98B
Total Assets	$18.51B	$18.89B	$17.62B
YoY Change	5.09%	4.38%	3.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$514.0M	$487.9M	$445.5M
YoY Change	15.38%	10.35%	2.29%
Accrued Expenses	$895.0M	$836.0M	$824.0M
YoY Change	8.62%	9.71%	6.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$129.0M	$115.0M	$120.0M
YoY Change	7.5%	-5.37%	-56.32%
Total Short-Term Liabilities	$2.399B	$2.411B	$2.089B
YoY Change	14.87%	-7.2%	-15.17%
LONG-TERM LIABILITIES
Long-Term Debt	$9.001B	$9.082B	$8.299B
YoY Change	8.46%	8.36%	1.94%
Other Long-Term Liabilities	$439.2M	$406.0M	$389.8M
YoY Change	12.68%	10.19%	2.49%
Total Long-Term Liabilities	$439.2M	$406.0M	$389.8M
YoY Change	12.68%	10.19%	2.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.399B	$2.411B	$2.089B
Total Long-Term Liabilities	$439.2M	$406.0M	$389.8M
Total Liabilities	$12.57B	$12.81B	$11.43B
YoY Change	9.97%	5.04%	-3.13%
SHAREHOLDERS EQUITY
Retained Earnings	$4.357B	$4.363B	$4.087B
YoY Change	6.6%	12.47%	21.5%
Common Stock	$1.119B	$1.107B	$1.108B
YoY Change	0.91%	514578.6%	520288.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$544.8M	$424.7M
YoY Change
Treasury Stock Shares	$7.366M	$5.623M
Shareholders Equity	$4.871B	$4.990B	$5.171B
YoY Change
Total Liabilities & Shareholders Equity	$18.51B	$18.89B	$17.62B
YoY Change	5.09%	4.38%	3.03%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$6.000M	$215.9M	$208.0M
YoY Change	-102.88%	17.24%	-2.01%
Depreciation, Depletion And Amortization	$163.3M	$162.1M	$153.6M
YoY Change	6.32%	8.65%	10.74%
Cash From Operating Activities	$436.7M	$679.0M	-$70.00M
YoY Change	-723.86%	-19.92%	-119.77%
INVESTING ACTIVITIES
Capital Expenditures	-$245.8M	$171.3M	-$197.8M
YoY Change	24.27%	3.9%	-9.31%
Acquisitions
YoY Change
Other Investing Activities	$514.4M	-$31.70M	-$248.7M
YoY Change	-306.84%	-85.81%	204.41%
Cash From Investing Activities	$268.6M	-$203.1M	-$446.5M
YoY Change	-160.16%	-47.7%	48.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-252.9M	-361.2M	-46.00M
YoY Change	449.78%	1.57%	-41.62%
NET CHANGE
Cash From Operating Activities	436.7M	679.0M	-70.00M
Cash From Investing Activities	268.6M	-203.1M	-446.5M
Cash From Financing Activities	-252.9M	-361.2M	-46.00M
Net Change In Cash	452.4M	114.7M	-562.5M
YoY Change	-180.43%	10.29%	2195.92%
FREE CASH FLOW
Cash From Operating Activities	$436.7M	$679.0M	-$70.00M
Capital Expenditures	-$245.8M	$171.3M	-$197.8M
Free Cash Flow	$682.5M	$507.7M	$127.8M
YoY Change	434.04%	-25.67%	-77.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2015	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	13781837000
CY2015	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	1220323000
CY2015	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	427860000
CY2015	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9052419000
CY2015	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	3509095000
CY2015	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	9480279000
CY2015	dva	Patient Care Costs PatientCareCosts	9824834000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1452135000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	638024000
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9240000
CY2015	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	18325000
CY2015	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	210234000
CY2013	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	13375000
CY2015	us-gaap	Profit Loss ProfitLoss	427410000
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	157678000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	269732000
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.27
CY2015	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.25
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83839000
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	211867714
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216251807
CY2015	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	269732000
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	13249000
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12241000
CY2014	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-10059000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3111000
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-10608000
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1413000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	238000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	377000
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	207000
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-23889000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22952000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-34809000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22372000
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	392601000
CY2014	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	840958000
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	157678000
CY2014	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	140216000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	234923000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	700742000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1499116000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	965241000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	408084000
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	337399000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1724228000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1525849000
CY2015Q4	us-gaap	Inventory Net InventoryNet	185575000
CY2014Q4	us-gaap	Inventory Net InventoryNet	136084000
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	435885000
CY2014Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	400916000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	190322000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	186842000
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	60070000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	4870780000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	5170513000
CY2015Q4	us-gaap	Minority Interest MinorityInterest	213392000
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	650075000
CY2015Q4	us-gaap	Liabilities Liabilities	12566637000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	389806000
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	726962000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59826000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25017000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	4503280000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	3636170000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2788740000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2469099000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1687326000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1864842000
CY2015Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	73368000
CY2014Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	65637000
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	94122000
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	89389000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73560000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77000000
CY2015Q4	us-gaap	Goodwill Goodwill	9294479000
CY2014Q4	us-gaap	Goodwill Goodwill	9415295000
CY2015Q4	us-gaap	Assets Assets	18514875000
CY2014Q4	us-gaap	Assets Assets	17617432000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	513950000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	445453000
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	682123000
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	510223000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	741926000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	698475000
CY2015Q4	dva	Medical Expense Payable MedicalExpensePayable	332102000
CY2014Q4	dva	Medical Expense Payable MedicalExpensePayable	314346000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	129037000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	120154000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2399138000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2088651000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9001308000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8298624000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	439229000
CY2014Q4	us-gaap	Liabilities Liabilities	11427156000
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	864066000
CY2014Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	829965000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	217000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	216000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1118326000
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1108211000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4356835000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4087103000
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	544772000
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	617597000
CY2014	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	272094000
CY2015	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	19715000
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5360311000
CY2014Q4	us-gaap	Minority Interest MinorityInterest	189798000
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5084172000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18514875000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17617432000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	264144000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	242674000
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217120346
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	215640968
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	209754247
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	215640968
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7366099
CY2015	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	638024000
CY2014	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	590935000
CY2013	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	528119000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	56664000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	56743000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	59998000
CY2015	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	45749000
CY2014	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	59119000
CY2013	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	46898000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	28157000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	45271000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	36197000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	61744000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	210955000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25380000
CY2015	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-9293000
CY2014	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-10125000
CY2013	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-2872000
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-44691000
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-39274000
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	31351000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	202867000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40676000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59640000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48313000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	46398000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8971000
CY2015	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-32761000
CY2014	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	61674000
CY2013	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	108434000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3723000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2916000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17731000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30998000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-8307000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	32360000
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-8941000
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	430000
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	938000
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	746000
CY2014	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	35382000
CY2013	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1305000
CY2015	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	129000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2956000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16666000
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	54950000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	97261000
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	38368000
CY2015	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	113470000
CY2014	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	83590000
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	78817000
CY2015	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-493775000
CY2014	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-410356000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	24175000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-60475000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	33354000
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1773341000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	641330000
CY2015	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	96469000
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	12445000
CY2014	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	472628000
CY2013	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1039000
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2058000
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2475000
CY2013	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	4158000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1637358000
CY2014	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	141072000
CY2013	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1376000
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1018000
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2391000
CY2015	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	17911000
CY2014	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	825000
CY2013	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	497000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-881784000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1277729000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-876882000
CY2015	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	54541988000
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	60038508000
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	66286097000
CY2015	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	53922290000
CY2014	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	60046487000
CY2013	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	66723385000
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	76672000
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	122988000
CY2014	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	225565000
CY2015Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	43393000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	272080000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	130977000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	114805000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	561255000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57811000
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	503444000
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	927761000
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	205071000
CY2015Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	83584000
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	13990000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1230406000
CY2015Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	726962000
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16423000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	28157000
CY2013	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	719000
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	549935000
CY2015	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	174635000
CY2014	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	149339000
CY2013	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	139326000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26155000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19500000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	45271000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	36197000
CY2015	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	54644000
CY2014	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	64655000
CY2013	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	36996000
CY2014	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3777000
CY2013	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	8295000
CY2015	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	66382000
CY2014	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	17876000
CY2013	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3569000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-138970000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-164979000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-482991000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2571000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2293000
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-967000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	533875000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18992000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	412501000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	946249000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533748000
CY2015	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inquiries by the Federal Government and Certain Related Civil Proceedings </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vainer Private Civil Suit</font>: As previously disclosed, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act. The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of $450,000 and attorney fees and other costs of $45,000 which was paid in 2015. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands further that certain other providers that operate dialysis clinics in New York may have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government and expects to execute in the first quarter of 2016 the settlement agreements with the government and the state of New York to finalize the terms of the settlement and to resolve this matter, and has accrued an amount that is immaterial.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Swoben Private Civil Suit</font>: In April 2013, the Company’s HCP subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed a <font style="font-style:italic;">qui tam</font> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a Settlement Agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services (CMS). In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font>: In February 2015, the Company announced that it received six administrative subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of each respective dialysis center. In February 2016, the Company received four additional subpoenas for four additional dialysis centers in southern California. The subpoenas were similarly limited in scope to the subpoenas received in 2015. The Company has been advised by an attorney with the United States Attorney’s Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation. The Company does not provide transportation nor does it bill for the transport of its dialysis patients. The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. OIG Medicare Advantage Civil Investigation</font>: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. Some of the information requested relates to what the Company first disclosed in the risk factors of the Company’s quarterly report on Form 10-Q for the first quarter of 2015 as a potentially improper historical HCP coding practice related to a particular condition. The practice in question was discontinued following the Company’s November 1, 2012 acquisition of HCP and, as the Company previously disclosed, the Company notified CMS of the coding practice and potential overpayments. In connection with the HCP merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company would pursue an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred. The Company can make no assurances that the indemnification and escrow would cover the full amount of the Company’s potential losses related to this matter. The Company is cooperating with the government and is producing the requested information. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Department of Justice Vascular Access Investigation</font>: In November 2015, the Company announced that RMS Lifeline, Inc., a wholly owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ). The CID relates to two vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these two centers in December 2012. Based on the language of the CID, the DOJ appears to be looking at whether the angiograms of 10 patients performed at the two centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides <font style="Background-color:#FFFFFF;">vascular access management services for dialysis patients</font>. The Company is in the process of producing the requested documents to the DOJ. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2016 U.S. Attorney Prescription Drug Investigation</font>: In early February 2016, the Company announced that its pharmacy services wholly owned subsidiary, DaVita Rx, received a CID from the U.S. Attorney’s Office for the Northern District of Texas. Based on the language of the CID, it appears the government is conducting an FCA investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues. The Company notified the government in September of 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. In the fourth quarter of 2015, the Company recorded an estimated accrual of $22 million for potential damages and liabilities associated with write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescriptions drugs, related to DaVita Rx that were identified during the course of this internal compliance review. The Company may accrue additional reserves for refunds and related damages and potential liabilities arising out of this review. Upon completion of its review, the Company filed a self-disclosure with the OIG in early February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlaps with information requested by the U.S. Attorney’s Office. The Company does not know if the U.S. Attorney’s Office, which is part of the DOJ, knew when it served the CID on the Company that it was already in the process of developing a self-disclosure to the OIG. The OIG informed the Company in late February that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. The Company intends to cooperate with the government in this matter<font style="color:#000000;">.</font></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shareholder Derivative Claims </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DaVita HealthCare Partners Inc. Derivative Litigation</font>: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney physician relationship investigations described above, the Vainer <font style="font-style:italic;">qui tam</font> private civil suit described above and the Woodard <font style="font-style:italic;">qui tam</font> private civil suit for which the Company previously announced a settlement in July 2012. The Company entered into a settlement with the lead plaintiff, which as previously disclosed, were described in a court-ordered notice sent to shareholders in late January 2015, and included enhancements to the Company’s corporate governance practices and provides that the Company will not oppose the derivative plaintiff’s application for an award of fees and expenses, the dollar amount of which is not material to the Company. The Court approved the settlement and entered an order granting final approval of the settlement on June 5, 2015 and final judgment in the case was entered on June 9, 2015.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the DOJ and certain agencies of the U.S. government. The Company has not received any further indication that any of these claims are active except for one payor claim relating to a special needs plan, and some of the other claims may be barred by applicable statutes of limitations. The Company is working to resolve the one active claim of which it is aware and, based on the dollar amount of the claim, expects that its eventual resolution will involve an amount that is immaterial.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2008, a wage and hour lawsuit was filed against the Company in the Superior Court of California which was styled as a class action and was subsequently amended. The complaint, as amended, alleged that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. After the Company prevailed on certain trial court rulings, the plaintiffs later appealed to the California Court of Appeals, and some of the issues on appeal were remanded to the trial court. The Company reached an agreement with the plaintiffs to settle the case in June 2015. The settlement has now been approved by the court. The amount of the settlement is not material to the Company’s consolidated financial statements. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows. </p></div>
CY2015	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	7134000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9918000
CY2014Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10123000
CY2015Q4	us-gaap	Senior Notes SeniorNotes	4500000000
CY2014Q4	us-gaap	Senior Notes SeniorNotes	3775000000
CY2015Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	70645000
CY2014Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	69045000
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	283185000
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9226330000
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8519642000
CY2015Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	95985000
CY2014Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	100864000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9130345000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	8418778000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	129037000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	152768000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	166132000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	740895000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	65171000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	7972327000
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets including goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements. </p></div>
CY2014Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3042776000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	484295000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	441225000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	282308000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	336588000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	147683000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	183289000
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2015Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	10
CY2015	dva	Percentage Of Voting Rights Held By Controlling Shareholder PercentageOfVotingRightsHeldByControllingShareholder	1.00
CY2015	dva	Ownership In Joint Venture OwnershipInJointVenture	0.50
CY2015Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	82679000
CY2015Q4	dva	Number Of Entities That Third Parties Held Non Controlling Ownership NumberOfEntitiesThatThirdPartiesHeldNonControllingOwnership	440
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	723114000
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	633446000
CY2014	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	214496000
CY2013	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	212128000
CY2013	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000
CY2013	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2013	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	0.07
CY2013	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	633446000
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2631000
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4194000
CY2014Q4	dva	Percentage Of Accounts Receivable Six Months Or More Past Due PercentageOfAccountsReceivableSixMonthsOrMorePastDue	0.11
CY2015Q4	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00
CY2015	dva	Accounts Receivable Period Outstanding AccountsReceivablePeriodOutstanding	P4M
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5531000
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	102466000
CY2014Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	81276000
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.80
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2015Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9310000
CY2014Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	24818000
CY2015Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	408000
CY2014Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	402000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1687326000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1864842000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167956000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	160960000
CY2014	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-1798000
CY2013	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-1447000
CY2015Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2014Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2015Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	68200000
CY2014Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	64203000
CY2014Q4	dva	Product Supply Agreement ProductSupplyAgreement	3997000
CY2014Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	10407000
CY2014Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	14404000
CY2014Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	4785000
CY2013	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	5330000
CY2015Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	406884000
CY2014Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	335975000
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	28123000
CY2014Q4	us-gaap	Marketable Securities MarketableSecurities	364098000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	33482000
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	440366000
CY2015Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	406884000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000
CY2014Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	335975000
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1424000
CY2015Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32282000
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	32282000
CY2014Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	26699000
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	26699000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	2589000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	5181000
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	1295000
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	1262000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	618000
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	340000
CY2015	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	377000
CY2014	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	207000
CY2013Q4	us-gaap	Goodwill Goodwill	9212974000
CY2014	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	221514000
CY2014	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1851000
CY2014	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-17342000
CY2015	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	97093000
CY2015	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	8781000
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	192834000
CY2015	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-16294000
CY2015	us-gaap	Goodwill Impaired Facts And Circumstances Leading To Impairment GoodwillImpairedFactsAndCircumstancesLeadingToImpairment	During the quarter ended December 31, 2015, and in conjunction with the annual goodwill impairment assessment for its HCP reporting units as of November 1, the Company determined that circumstances indicated it had become more likely than not that the goodwill and an indefinite-lived intangible asset of certain HCP reporting units had become impaired. These circumstances included underperformance of the business in recent quarters as well as changes in other market conditions, including government reimbursement cuts and our expected ability to mitigate them. We are performing the required “step 1” and “step 2” valuations for these HCP reporting units and have estimated the fair value of their net assets and implied goodwill with the assistance of a third-party valuation firm. The Company also recorded a minor goodwill impairment charge on one of its international operations during 2015.
CY2015	us-gaap	Goodwill Impaired Change In Estimate Description GoodwillImpairedChangeInEstimateDescription	For example, a sustained, long-term reduction of 3% in operating income for HCP Nevada or HCP Florida could reduce their estimated fair values by up to 2.0% and 1.6%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP Nevada and HCP Florida by up to 2.9% and 2.8%, respectively.
CY2015Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	153104000
CY2014Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	125435000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	29050000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15614000
CY2015Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	80355000
CY2014Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	92928000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81585000
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	87224000
CY2015Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	53687000
CY2014Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	39867000
CY2015Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	29291000
CY2014Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	25909000
CY2015Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	255051000
CY2014Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	123246000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	188302000
CY2015	dva	Increase Decrease In Prior Year Estimates Of Health Care Costs Payable IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable	1523000
CY2014	dva	Increase Decrease In Prior Year Estimates Of Health Care Costs Payable IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable	3429000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	183263000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.113
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	334258000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	30766000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	30789000
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	68715000
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	856000
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1687000
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1764000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	214885000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	220778000
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	404737000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	88718000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	192267000
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6695000
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	80841000
CY2013	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-14890000
CY2015	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	295726000
CY2014	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	446343000
CY2013	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	389847000
CY2013	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-84000
CY2013	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	8918000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.001
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.117
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.026
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.006
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.003
CY2013	dva	Effective Income Tax Rate Reconciliation Contingent Earn Out Adjustments EffectiveIncomeTaxRateReconciliationContingentEarnOutAdjustments	-0.026
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.040
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.041
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.409
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.341
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.339
CY2014Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	42976000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	253228000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102212000
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	93567000
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	491983000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28784000
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	463199000
CY2014Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	839824000
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	187198000
CY2014Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	78619000
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7633000
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1113274000
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29027000
CY2014Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	650075000
CY2015Q2	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	450000000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	514287000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	120775000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	460093000
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	424096000
CY2015Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	261960000
CY2014Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	197344000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	31877000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6131000
CY2015	dva	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2999000
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1996000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39011000
CY2014	dva	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-27312000
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	218097000
CY2014Q2	dva	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	1500000000
CY2015	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0442
CY2015Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0439
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	389755000
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	385750000
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	401140000
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18625000
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24544000
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28803000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	431658000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	415746000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	375516000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	331575000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	283633000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1083825000
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2921953000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	30538000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	30848000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	31196000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	32065000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	32443000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	235285000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	392375000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	109190000
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	283185000
CY2015Q2	us-gaap	Legal Fees LegalFees	45000000
CY2015Q4	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	22000000
CY2015	us-gaap	Unrecorded Unconditional Purchase Obligation Description UnrecordedUnconditionalPurchaseObligationDescription	Certain consolidated joint ventures are originally contractually scheduled to dissolve after terms ranging from 10 to 50 years.
CY2013Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2
CY2013Q3	us-gaap	Dividend Payable Date To Be Paid Day Month And Year DividendPayableDateToBePaidDayMonthAndYear	2013-09-06
CY2013Q3	us-gaap	Dividends Payable Date Of Record Day Month And Year DividendsPayableDateOfRecordDayMonthAndYear	2013-08-23
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	8533561
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	59.05
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2856959
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	47.88
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	116933000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	151342000
CY2013	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	628885000
CY2014	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	136000
CY2014	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-5002000
CY2013	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-4561000
CY2015	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	213906000
CY2014	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	718112000
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	273614000
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	738991000
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	1.29
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.48
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	1.27
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.41
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	157397000
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	62655000
CY2015	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	130682000
CY2014	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	118970000
CY2013	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	84841000
CY2015	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	19689000
CY2014	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	20351000
CY2013	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	22187000
CY2015Q4	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	123966000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	63599000
CY2015	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y
CY2015	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	45749000
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	59119000
CY2013	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	46898000
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2014	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2015	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	7779958
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	575380000
CY2015	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	73.96
CY2015Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	725944000
CY2010Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	274056000
CY2014	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0
CY2013	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0
CY2015	us-gaap	Targeted Or Tracking Stock Corporate Events TargetedOrTrackingStockCorporateEvents	The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-55826000
CY2013	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	209000
CY2015	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P8Y
CY2014	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2013	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y
CY2015Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	73733000
CY2014Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	175247000
CY2013Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	221454000
CY2014Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	39129000
CY2015	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	990000
CY2015	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	428000
CY2015	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	5556000
CY2015Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	34135000
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	13798581000
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	13040206000
CY2015Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	706978000
CY2015	us-gaap	Concentration Risk Customer ConcentrationRiskCustomer	There is no single commercial payor that accounted for more than 10% of total consolidated accounts receivable at December 31, 2015 and 2014.
CY2015Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	330213000
CY2015	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	18965000
CY2014	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	13012000
CY2013	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	53699000
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	156075000
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	238615000
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	341426000
CY2015	us-gaap	Interest Paid InterestPaid	405120000
CY2014	us-gaap	Interest Paid InterestPaid	351967000
CY2013	us-gaap	Interest Paid InterestPaid	405030000
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	74035000
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	72389000
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	60920000
CY2015Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3533589000
CY2015Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3525665000
CY2015Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3434618000
CY2015Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3287965000
CY2014Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3328017000
CY2014Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3251824000
CY2014Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3172489000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	244935000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	509368000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	480548000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-64156000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	452085000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	437536000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	146307000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	408371000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	330539000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-162081000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	354365000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	336412000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-6000000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	215872000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	170477000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-110617000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	208020000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	184122000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.02
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.80
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.52
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.98
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.87
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.70
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.87
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2015Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.03
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.00
CY2015Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.78
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.52
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.96
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.68
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.00
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2015	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	456452000
CY2014	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	507842000
CY2013	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	429943000
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13236000
CY2015Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1279936000
CY2015Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	241050000
CY2015Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10167499000
CY2014Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1145080000
CY2014Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	232026000
CY2014Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9338505000
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1129790000
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	19715000
CY2015	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	97032000
CY2015	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	619698000
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-758668000
CY2014	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	596077000
CY2014	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	8791000
CY2014	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	373096000
CY2014	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-7989000
CY2014	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-156990000
CY2013	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1016140000
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	62258000
CY2013	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	11149000
CY2013	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-438007000
CY2013	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-44984000
CY2015	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	96469000

Files In Submission

Name	View Source	Status
0001564590-16-013587-index-headers.html	Edgar Link	pending
0001564590-16-013587-index.html	Edgar Link	pending
0001564590-16-013587.txt	Edgar Link	pending
0001564590-16-013587-xbrl.zip	Edgar Link	pending
dva-10k_20151231.htm	Edgar Link	pending
dva-20151231.xml	Edgar Link	completed
dva-20151231.xsd	Edgar Link	pending
dva-20151231_cal.xml	Edgar Link	unprocessable
dva-20151231_def.xml	Edgar Link	unprocessable
dva-20151231_lab.xml	Edgar Link	unprocessable
dva-20151231_pre.xml	Edgar Link	unprocessable
dva-ex121_6.htm	Edgar Link	pending
dva-ex211_7.htm	Edgar Link	pending
dva-ex231_8.htm	Edgar Link	pending
dva-ex311_9.htm	Edgar Link	pending
dva-ex312_10.htm	Edgar Link	pending
dva-ex321_11.htm	Edgar Link	pending
dva-ex322_12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2015 Q4 Form 10-K Financial Statement

#000156459016013587 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2015 Q4 Form 10-K Financial Statement

#000156459016013587 Filed on February 26, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva